Navigation Links
Genomic Health to Present at the Canaccord Genuity Growth Conference
Date:8/7/2012

REDWOOD CITY, Calif., Aug. 7, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the Company will present at the 32nd Annual Canaccord Genuity Growth Conference in Boston on Tuesday, August 14, 2012 at 2:00 p.m. Eastern Time (ET). 

To access the live and subsequently archived webcast of the presentation, visit the Investor Relations section of Genomic Health's website at http://investor.genomichealth.com.  Please connect to the website at least 15 minutes prior to the beginning of the presentation to allow for any necessary software downloads.  An archived replay will be available for three months beginning 24 hours after the live presentation.

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is a global health company that provides actionable genomic information to personalize genomic health decisions. The company's lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS).  In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease.  As of March 31, 2012, more than 10,000 physicians in over 65 countries had ordered more than 275,000 Oncotype DX tests.  Genomic Health has a robust pipeline focused on developing tests to optimize the treatment of prostate and renal cell cancers, as well as additional treatment decisions in breast and colon cancers.  The company is based in Redwood City, California with European headquarters in Geneva, Switzerland.  For more information, please visit, www.GenomicHealth.com.  To learn more about Oncotype DX tests, visit: www.OncotypeDX.com and www.mybreastcancertreatment.org.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the attributes and focus of the company's product pipeline, the ability of the company to develop additional tests in the future, and the ability of any potential tests the company may develop to optimize cancer treatment. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests; unanticipated costs or delays in research and development efforts; our ability to obtain capital when needed and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Annual Report on Form 10-Q for the quarter ended March 31, 2012. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners


'/>"/>
SOURCE Genomic Health, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Genomic Health to Announce Second Quarter 2012 Financial Results and Host Conference Call on Wednesday, August 8, 2012
2. Elsevier Launches New Open Access Journal: Applied and Translational Genomics
3. Life Technologies Acquires Pinpoint Genomics and CLIA-Approved Lung Cancer Test
4. Life Technologies Signs Collaborative Agreement with Structural Genomics Consortium to Develop First Antibody Master Set for Epigenetic Studies
5. Gentris Corporation Launches New Pharmacogenomics Services
6. Rubicon Genomics Launches ThruPLEX™ Family of Sample Preparation Products for Next Generation Sequencing Applications
7. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
8. Genomic Health to Announce First Quarter 2012 Financial Results and Host Conference Call on Wednesday, May 2, 2012
9. Empire Genomics Chooses Funakoshi as Japan Distributor
10. Asthmapolis Expands Dignity Health Study to Include Mercy Medical Group Patients
11. The Medicus Firm Named 2012 "Best Places to Work in Healthcare" by Modern Healthcare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), ... the Urology, Uro/Gyn and Gynecology markets with innovative ... has joined the Company as Senior Vice President, ... position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has joined ...
(Date:4/20/2017)... -- Research and Markets has announced the ... Prospects: Addressing Production Complexities Through Risk Management and Quality ... ... and Market Prospects: Overcoming Production Complexities Through Risk Management ... the current trends in the global biosimilars market, with ...
(Date:4/20/2017)... April 20, 2017  CVS Pharmacy, the retail ... a new store design to enhance the retail ... food, health-focused products and expanded beauty selections paired ... customers discover new offerings. Together with its innovative ... of the customer experience at CVS Pharmacy.  ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... 2017 , ... Providing broad access to life-saving drugs and rewarding the innovators ... way to address this problem. , That was the message from Dana Goldman, PhD, ... the University of Southern California, who served as the keynote speaker for Western University ...
(Date:4/21/2017)... ... April 21, 2017 , ... Chicago plastic surgeon, Dr. Anil R. ... osteoma is a benign bony lump located on the forehead usually attributed to a ... with sight and pain. Dr. Shah has discovered an approach that is minimally invasive. ...
(Date:4/21/2017)... PA (PRWEB) , ... April 21, 2017 , ... ... firm in Allegheny County that offers services to communities throughout the greater Pittsburgh ... in a charity drive to provide adaptive bicycles for differently-abled children. , Variety ...
(Date:4/21/2017)... ... April 21, 2017 , ... The Patient Advocacy Community of The ... the 2017 Ruth Ravich Patient Advocacy Award in recognition of her extraordinary ... honored with the award at The Beryl Institute’s annual Patient Experience Conference ...
(Date:4/21/2017)... ... 21, 2017 , ... Crossover Symmetry , an evidence ... active lifestyle company that provides Human Performance Training and education to tactical athletes. ... responders, military officers and others in service through the development and conditioning of ...
Breaking Medicine News(10 mins):